Donken R, et al. - Researchers here determined the vaccine effectiveness (VE) of the bivalent HPV-vaccine against incident and 12-month persistent infections up to six years post-vaccination. In this population-based cohort study, findings revealed nearly full protection against vaccine-type persistent infections and significant cross-protection to non-vaccine types. Findings, hereby, confirmed the effectiveness of the bivalent HPV vaccine as estimated in trials. No indications for waning were identified up to six years post-vaccination.